Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q39975802)
Watch
English
State-of-the-art treatment of metastatic renal cell carcinoma.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
title
State-of-the-art treatment of metastatic renal cell carcinoma
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
author name string
D Y C Heng
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
C Kollmannsberger
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
1 May 2009
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
published in
Current Oncology
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
volume
16 Suppl 1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
page(s)
S16-23
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
copyright license
Creative Commons Attribution 4.0 International
start time
1 May 2009
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Targeted therapy for advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Cancer statistics, 2008
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Sunitinib efficacy against advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Sorafenib in advanced clear-cell renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Immunotherapy for advanced renal cell cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Systemic therapy for renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
22 September 2017
Cytotoxic chemotherapy for advanced renal cell carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
25 September 2017
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
17 June 2018
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
17 June 2018
Mutations of the VHL tumour suppressor gene in renal carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
17 June 2018
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
Renal-Cell Carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
Kinase inhibition with BAY 43-9006 in renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687801
retrieved
20 August 2018
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478897
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.3747/CO.V16I0.407
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PMC publication ID
2687801
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PubMed publication ID
19478897
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687801
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
